Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 2 for:    inivata
Previous Study | Return to List | Next Study

Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Inivata
Sponsor:
Collaborator:
Vector Oncology
Information provided by (Responsible Party):
Inivata
ClinicalTrials.gov Identifier:
NCT02906852
First received: September 2, 2016
Last updated: March 31, 2017
Last verified: March 2017
  Purpose
The aim of this study is to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced lung cancer.

Condition
Non-Small Cell Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Study to Evaluate the Performance of Inivata Liquid Biopsy Compared With Standard Tissue Biopsy for Detection of Genomic Alterations in Patients With Advanced Non Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Inivata:

Primary Outcome Measures:
  • Concordance in the detection of molecular abnormalities using Inivata's liquid biopsy panel with detection using standard of care tissue biopsy analysis [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Detection: sensitivity and specificity of molecular abnormalities using Inivata liquid biopsy panel relative to standard of care tissue biopsy analysis [ Time Frame: 1 year ]
  • Proportion of NSCLC patients eligible for targeted therapy based on liquid biopsy analysis as an evaluation of feasibility molecular stratification, compared to standard of care alone [ Time Frame: 1 year ]
  • Progression free survival (PFS) rate over 6 months [ Time Frame: 1 year ]
  • Overall survival (OS) rate over 6 months [ Time Frame: 1 year ]

Other Outcome Measures:
  • Relationship of clinical response to therapy with mutation allele frequency (MAF) cutoff in Inivata liquid biopsy assay [ Time Frame: 1 year ]

Biospecimen Retention:   Samples With DNA
A 40ml blood sample will be taken, from which Plasma and ultimately DNA/RNA will be prepared.

Estimated Enrollment: 310
Study Start Date: August 2016
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Detailed Description:

The aim of this study is to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced lung cancer. Once selected for the study and with full informed consent, patients will have a blood draw to allow the detection of cancer-related genomic alterations that are detectable within the blood sample. These results will be compared to results obtained from genomic profiling via standard tissue biopsy taken as part of routine care to help determine whether such 'liquid biopsies' can be used to guide treatments in future patients. The results of the liquid biopsy will not be used to guide treatment decisions in study participants.

In addition there is data-collection of treatments received for non small cell lung cancer and the response to these treatments during the first 6 months post tissue and blood analysis, though no additional visits or procedures are required for the patient beyond the initial blood draw.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male and female patients aged 18 years and over diagnosed with stage IIIb/IV non-squamous NSCLC, who are intended to initiate first-line treatment according to standard guidelines, or having recently progressed on first-line EGFR or ALK directed therapy and being considered for further therapy.
Criteria

Inclusion Criteria:

  • Written, signed and dated informed consent to participate in the study must be given by the patient in accordance with 21 CFR Part 312, the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6, and applicable regulations, before completing any study-related procedures.
  • Male and female patients aged 18 years and over diagnosed with stage IIIb/IV non-squamous NSCLC.
  • Patients intended to initiate first-line treatment according to standard guidelines, or having recently progressed on first-line EGFR or ALK directed therapy and being considered for further therapy. If enrolled in a treatment clinical trial, patients may enroll in this study if all eligibility criteria are met.
  • Patients who plan to have or have had a recent tumor tissue biopsy taken for molecular profiling as part of their standard of care.
  • Patient must understand and be able, willing and likely to fully comply with all study procedures and restrictions.

Exclusion Criteria:

  • Patients who have received any approved or experimental cancer therapy since their most recent NSCLC tissue biopsy.
  • Patients who have any other prior metastatic or current second primary cancer.
  • Patient who has a severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02906852

Contacts
Contact: Molly Bur 1-901-574-4601 mbur@vectoroncology.com
Contact: Susan Cole 1-901-435-5571 scole@vectoroncology.com

  Show 22 Study Locations
Sponsors and Collaborators
Inivata
Vector Oncology
Investigators
Principal Investigator: Ramaswamy Govindan, MD Washington University School of Medicine
Principal Investigator: Edward Kim, MD Levine Cancer Institute
Study Director: Clive Morris, MD Inivata
  More Information

Responsible Party: Inivata
ClinicalTrials.gov Identifier: NCT02906852     History of Changes
Other Study ID Numbers: INI001
Study First Received: September 2, 2016
Last Updated: March 31, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 27, 2017